TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02539342
Drug: Caphosol
Normalized name: Caphosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the Caphosol Arm will use Caphosol 4 times per day as follows:~* Each dose consists of two 15 mL syringes, to be mixed at time of administration. Caphosol must be used within 15 minutes of mixing.~  o Participants may increase the use to 6 times per day if you have symptoms of mucositis.~* Using one of the syringes, rinse and gargle (if patient is able) for one minute and then spit. Repeat using the remaining syringe.~  * For younger patients (less than or equal to 6 years of age), volume may be reduced to two syringes containing 5-10 mL each.~ * For patients unable to successfully rinse and spit, caregivers may paint their mouth (using medical sponge swabs) with the solution two times. Repeat using the second syringe.~* Patients are to avoid other oral medications, other mouth cares and food or drink for 15 minutes after using Caphosol.~* Patients may use Biotene (5-10 mL) to swish and spit after the 15 minutes has passed
Study: NCT02029352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composition, apart from the active substance, is otherwise identical to the investigational medical product.
Study: NCT00111475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT01308723
Drug: RO5323441
Approvals — FDA: no, EMA: no, PMDA: no
Description: escalating doses iv
Study: NCT01308723
Drug: RO5323441
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv every 2 weeks
Study: NCT01593163
Drug: Ibuprofen EchoG
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infants in the experimental group (echoG treatment) received additional doses of ibuprofen only if PDA was still ≥ 1.5 mm at the time of the corresponding ibuprofen dose.
Study: NCT01593163
Drug: Standard ibuprofen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants received 3 doses of ibuprofen at 24-hour intervals, independently of ductal size, as long as additional doses were not contraindicated.
Study: NCT02501343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodibic-matching placebo (Stenlake Compounding Chemist, NSW, Australia) will be administered prior to the meal on a different day 1 to 2 weeks apart
Study: NCT01816594
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant BKM120 (oral pan-class I PI3K inhibitor, continuous daily dosing). BKM120 was administered orally 100 mg/day.
Study: NCT01206478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (looks like study drug but has no active ingredients) once daily at bedtime.
Study: NCT01816594
Drug: BKM120 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant BKM120 placebo Administered orally 100 mg/day.
Study: NCT01951430
Drug: Antibiotic and antifungal drugs
Normalized name: Antifungal Antibiotics, Topical
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03905655
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of placebo tablets administered orally depends on the arm
Study: NCT04363801
Drug: Capecitabine 1000mg/ m2 BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04363801
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by IV infusion
Study: NCT04363801
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by IV infusion
Study: NCT03446651
Drug: Lysine Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 7 days of therapy using 115 mmol/day of lysine chloride. Patients will be given the option of a taste test of both lysine chloride \& the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.
Study: NCT01516047
Drug: Cohort 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg to 2000 mg abiraterone acetate suspension on Day 1
Study: NCT01516047
Drug: Cohort 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg abiraterone acetate suspension on Day 1
Study: NCT03353753
Drug: DCC-2618
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral KIT/PDGFRA kinase inhibitor
Study: NCT03353753
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00990158
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A daily dose of matching placebo medication given orally for a total of 7 months
Study: NCT02704494
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 capsule daily
Study: NCT04626193
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycylcine 100 mg bid ,esomprazole 20 bid,levofloxacineq.d,Tinadizole 500 bid
Study: NCT03441893
Drug: Placebo tabletes
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tab. Placebo (shugar pills) will be given to the participants
Study: NCT01546896
Drug: buspirone+alprazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: day 1\~7: buspirone 10mg/d + alprazolam 0.5mg / day 8\~28: buspirone 20mg/d + alprazolam 0.5mg / day 29\~56: buspirone 20\~30mg/d + alprazolam 0.5mg
Study: NCT00218426
Drug: placebo implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo implant resembles active medication
Study: NCT03286712
Drug: Renogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of erythropietin alpha to see the effect on the hemoglobin level and vascular reactivity
Study: NCT03953092
Drug: YG1699
Approvals — FDA: no, EMA: no, PMDA: no
Description: YG1699 at Multiple Doses
Study: NCT03953092
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos
Study: NCT02353039
Drug: GC6101A 37.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer 12.5mg of GC6101A t.i.d for 2 weeks.
Study: NCT02353039
Drug: GC6101A 75mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer 25mg of GC6101A t.i.d for 2 weeks.
Study: NCT02353039
Drug: GC6101A 150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer 50mg of GC6101A t.i.d for 2 weeks.
Study: NCT02353039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer placebo t.i.d for 2 weeks
Study: NCT00089453
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A dose of 60mg/kg (using calculated body weight - see appendix A.) will be infused on day-3, and -2. Cyclophosphamide is administered by intravenous infusion over 2-4 hrs in 250 mLs of Normal Saline (0.9%) or D5W Standard MESNA (60% or 36mg/kg) protection to prevent hemorrhagic cystitis will be given on day -3, -2 and -1.
Study: NCT01603069
Drug: AZD3241 300 mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: The following dose escalation schedule will be used for 300 mg BID: 100 mg BID from Day 1 through Day 7. On Day 8, the patients will start maintenance treatment of 300 mg BID for the duration of the treatment period.
Study: NCT01603069
Drug: AZD3241 600 mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: The following dose escalation schedule will be used for 600 mg BID: 100 mg BID from Day 1 through Day 7 and 300 mg BID from Day 8 through Day 14. On Day 15, the patients will start maintenance treatment of 600 mg BID for the duration of the treatment period.
Study: NCT01603069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to AZD3241 BID
Study: NCT01358968
Drug: LY2603618
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously as a 1-hour infusion.
Study: NCT01358968
Drug: Desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03033823
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (i.e. without any restriction of drug therapy) plus oral placebo, totally similar to the verum, three times daily throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used.
Study: NCT03593655
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet containing 200 mg FTC/300 mg TDF
Study: NCT01362218
Drug: Simvastatin, ramipril, acetylsalicylic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: A once daily oral dose of simvastatin, ramipril, acetylsalicylic acid for 8 weeks
Study: NCT02271126
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anticoagulation provided to patients in ECMO
Study: NCT01771458
Drug: Standard Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00688636
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
Study: NCT00566267
Drug: simvastatin 20 mg/ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: see protocol
Study: NCT01518712
Drug: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
Study: NCT01518712
Drug: B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
Study: NCT01478568
Drug: desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT02586233
Drug: DS-1040b
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-1040b for IV infusion (0.6 mg to 9.6 mg) over 6-hour period
Study: NCT02586233
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride (placebo comparator) for IV infusion over 6-hour period
Study: NCT01690169
Drug: NNC0113-0987
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose for oral administration, up to 7 dose levels will be investigated. If a non-tolerated dose level has been reached, the dose level will not be increased further.
Study: NCT01690169
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of oral placebo administered.
Study: NCT04379219
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: giving methotrexate at least 1 w week before surgery
Study: NCT00193219
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 350 mg IV
Study: NCT02462941
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testing escalating doses of adenosine in pediatric heart transplant patients
Study: NCT00996021
Drug: GSK1349572 250 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an experimental HIV medication in the integrase inhibitor class.
Study: NCT00996021
Drug: Placebo Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a liquid with no drug in it.
Study: NCT01418053
Drug: caraway oil
Normalized name: Caraway Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: essential oil, Carum carvi, 2% dissolved in olive oil, 1 teaspoon with caraway oil used externally as inunction together with a hot cataplasm
Study: NCT00934427
Drug: vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5g of vehicle cream is topically administered BID for one day before certain planned cold exposures, once just before certain planned cold exposures, and, if needed, right after the start of symptoms during certain planned cold exposures
Study: NCT03424824
Drug: BP1.3656 low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, once daily oral administration at the low dose
Study: NCT03424824
Drug: BP1.3656 intermediate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, once daily oral administration at the intermediate dose
Study: NCT03424824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, once daily oral administration
Study: NCT03424824
Drug: BP1.3656 high dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, once daily oral administration at the high dose
Study: NCT02952924
Drug: RO7049389
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7049389 will be administered as per schedule described in individual arm.
Study: NCT02158299
Drug: Avitene
Normalized name: Avitene
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02567214
Drug: Ultibro®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention in this arm is the Ultibro®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be delivered and the Spiriva will be a placebo. We will measure the exertional dyspnea after 21 days of treatment.
Study: NCT02567214
Drug: Spiriva®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention in this arm is the Spiriva®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be a placebo and the Spiriva will be delivered. We will measure the exertional dyspnea after 21 days of treatment.
Study: NCT00091312
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00091312
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01122030
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets or solution for oral administration
Study: NCT00091312
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01581281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance period.
Study: NCT00544011
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00544011
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02094053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (oral) once daily, for 24 weeks
Study: NCT00501046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9g /day (3 times a day)
Study: NCT00501046
Drug: AST-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9g /day (3 times a day)
Study: NCT05166746
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clindamycin 300mg/2xdaily in 7 days. LACTIN-V applicators 1x at night in 7 days, then 2xper week at night for 7 weeks.
Study: NCT00139685
Drug: Depo-Provera Contraceptive Injection - DP150CI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01266434
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg once daily for 8 weeks
Study: NCT01567618
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil 400mg/m2 iv D1; Fluorouracil 2400mg/m2 civ 46 hours; repeat fortnightly and evaluate every two cycles
Study: NCT03580876
Drug: addition of azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: impact of addition of azathioprine after a switch of a second anti-TNF agent
Study: NCT03580876
Drug: Switch to a second anti-TNF drug alone
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to a second anti-TNF drug alone without addition of azathioprine
Study: NCT00698789
Drug: INCB019602
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of INCB019602 in AM with placebo administration in PM
Study: NCT00698789
Drug: INCB019602
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg in PM with placebo administration in AM
Study: NCT00698789
Drug: INCB019602
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg in PM with placebo administration in AM
Study: NCT00698789
Drug: INCB019602
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg in PM QoD with placebo administration in AM as well as PM on non-active dose days
Study: NCT00698789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration in AM or PM depending on treatment arm dosing regimen.
Study: NCT03342638
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Potent immunosuppressive agent; an alkylating agent
Study: NCT00450086
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g per day
Study: NCT01666691
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses.
Study: NCT02581111
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02182141
Drug: BIBF 1120 ES
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01507168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv Days 1 and 8, and every 2 weeks thereafter
Study: NCT04403698
Drug: Alendronate Effervescent Oral Tablet
Normalized name: alendronate Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the earliest three months but no later than four months after the last denosumab injection, subjects will be randomized to effervescent alendronate administered for either 24 or 48 weeks
Study: NCT01844830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredients supplied in identical nasal sprayer
Study: NCT02300220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule, twice daily for 1 week
Study: NCT02035982
Drug: Cholinesterase Inhibitor
Normalized name: Acetylcholinesterase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: For participants randomized into the active treatment arm, they will be provided with the following study medications:~Donepezil - 5 mg or 10 mg Galantamine - 8 mg and 16 mg and 24 mg Rivastigmine - 1.5 mg and 3 mg~The type of study medication provided will depend on the type and dosage of the cholinesterase inhibitor they have been receiving for the last 3 months of their regular treatment. For example, if that have been taking Donepezil - 5 mg daily, they will continue on that same medication, dosage and frequency.
Study: NCT02035982
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For participants randomized into the placebo intervention, placebo capsules will match capsules in the active intervention.
Study: NCT03336619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally twice daily for five days
Study: NCT01446458
Drug: Modified FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive modified FOLFIRINOX Chemotherapy for 4 cycles (1 cycle = 15 days). Modified FOLFIRINOX: Oxaliplatin 85 mg/m2 intravenous infusion on day 1; Irinotecan 180 mg/m2 intravenous infusion on day 1; 5-Fluorouracil 2400 mg/m2 continuous intravenous infusion on days 1 to 3; pegylated filgrastim (neulasta) 6 mg subcutaneous injection on day 3.
Study: NCT00240552
Drug: Telzir®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02634931
Drug: NPC-12G gel
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPC-12G gel is administered topically twice a day for 52 weeks or longer
Study: NCT00168025
Drug: Immunoglobulins Intravenous (Human)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04591795
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium, 25 mg enteric-coated tablets
Study: NCT00605410
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT00618449
Drug: Azithromcyin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given 30 days apart; at Day 0 \& Day 30 for a total of 2 doses.
Study: NCT00618449
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given at Day 30 for a total of 1 dose.
Study: NCT04741334
Drug: direct anticoagulant
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: exposure to direct anticoagulant
Study: NCT04741334
Drug: Dicumarols
Approvals — FDA: no, EMA: no, PMDA: no
Description: exposure to dicumarols
Study: NCT04474119
Drug: KN046 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In combine therapy stage, KN046 placebo is 5 milligram per kilogram, every 3 weeks.~In maintain stage, KN046 placebo is 5 milligram per kilogram, every 2 weeks.
Study: NCT02235987
Drug: DG3173
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.